Welcome! Login | Register
 

Friday Financial Five: November 28th, 2014—It’s a busy time for the economic calendar

10 Recipes for Thanksgiving Leftovers—Thanksgiving is over and you are still left…

Finneran: Lord, For These Many Things I Am Grateful—Americans need Thanksgiving

Happy Thanksgiving Central MA—This holiday season, be sure to give love,…

25 Ways to Give in Central MA this Holiday Season—The holidays are a time of giving -…

Celebrate Thanksgiving Weekend at Old Sturbridge Village with Your WOO Card—The weekend is fast approaching, and GoLocalWorcester brings…

Newport Manners & Etiquette: Thanksgiving & More—Last minute Thanksgiving etiquette questions you may also…

Harr Motor Group Donates Coats to Families in Need—Worcester”s Harr Motor Group’s Coats for Kids program…

The Cellar: Thanksgiving Add-Ons—Thanksgiving is upon us and if you’re into…

Paul Giorgio: The Political Roots of Thanksgiving—Tomorrow we celebrated Thanksgiving, the most political of…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.